Companies › ModernaTX
23 active drug programs in 33 registered trials: 21 Phase 1, 5 Phase 4, 5 Phase 2, 2 Phase 3; Infectious disease, Oncology, Metabolic and endocrine, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tozinameran (mRNA-1273) Spike glycoprotein vaccine antigen | – | Phase 4 | SARS-CoV-2 | Dec 2026 |
| mRNA-1283 mRNA vaccine | – | Phase 4 | SARS-CoV-2 | Dec 2026 |
| mRNA-1273 Variant-containing Formulation mRNA vaccine encoding SARS-CoV-2 spike protein variants | – | Phase 4 | SARS-CoV-2 | Dec 2026 |
| mRNA-1018-H5 mRNA vaccine encoding influenza H5 hemagglutinin | – | Phase 3 | Influenza | Jan 2027 |
| mRNA-1403 mRNA vaccine encoding norovirus virus-like particles | – | Phase 3 | Acute Gastroenteritis; Norovirus Acute Gastroenteritis | Feb 2027 |
| mRNA-1647 mRNA vaccine expressing CMV antigens | CMV | Phase 2 | Cytomegalovirus Infection | Mar 2027 |
| mRNA-4157 Personalized neoantigen mRNA vaccine | – | Phase 2 | Melanoma; Solid Tumors | Nov 2027 |
| mRNA-1982 mRNA vaccine targeting Borrelia burgdorferi outer surface protein A (OspA) | – | Phase 2 | Lyme Disease | Nov 2028 |
| mRNA-1195.1 mRNA vaccine encoding Epstein-Barr virus (EBV) antigens - formulation variant | – | Phase 2 | Multiple Sclerosis; Epstein-Barr Virus Infection | Jan 2029 |
| mRNA-3745 mRNA therapy encoding glucose-6-phosphatase | G6PC | Phase 1 | Glycogen Storage Disease | Nov 2026 |
| mRNA-0184 mRNA therapeutic | – | Phase 1 | Healthy Participants | Dec 2026 |
| mRNA-1189 mRNA vaccine encoding Epstein-Barr virus antigens | EBNA1, LMP1, BZLF1 | Phase 1 | Epstein-Barr Virus Infection; Epstein-Barr Virus | May 2027 |
| mRNA-1365 (Profile 2) mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) | RSV, HMPV | Phase 1 | Respiratory Syncytial Virus (RSV); Respiratory Syncytial Virus | Jul 2027 |
| mRNA-4106 Personalized neoantigen mRNA vaccine | – | Phase 1 | Advanced Solid Tumors | Aug 2027 |
| mRNA-4200 Personalized neoantigen mRNA vaccine | – | Phase 1 | Advanced Solid Tumors | Aug 2027 |
| mRNA-3927 mRNA therapy encoding propionyl-CoA carboxylase beta subunit | PCCB | Phase 1 | Propionic Acidemia | Aug 2027 |
| mRNA-1469 mRNA vaccine expressing Ebola-Bundibugyo virus antigens | – | Phase 1 | Ebola-Bundibugyo Virus Disease (Ebola-BDBV) | Sep 2027 |
| mRNA-1010 mRNA vaccine encoding seasonal influenza antigens | – | Phase 1 | Seasonal Influenza | Dec 2027 |
| mRNA-1345 mRNA vaccine targeting respiratory syncytial virus (RSV) | RSV | Phase 1 | Respiratory Syncytial Virus | Aug 2029 |
| mRNA-2808 Immunomodulatory mRNA therapeutic | – | Phase 1 | Relapsed or Refractory Multiple Myeloma | Jun 2030 |
| mRNA-4359 Personalized neoantigen vaccine | – | Phase 1 | Advanced Solid Tumors | Feb 2032 |
| mRNA-3705 modified mRNA encoding human methylmalonyl-coenzyme A mutase (MUT) | MMUT | Phase 1 | Methylmalonic Acidemia | Apr 2034 |
| mRNA-1405 mRNA vaccine encoding norovirus antigens | – | Phase 1 | Norovirus Acute Gastroenteritis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05992935 | mRNA-1403 | Phase 1 | Norovirus Acute Gastroenteritis | Infectious disease | Oct 2026 |
| NCT05992935 | mRNA-1405 | Phase 1 | Norovirus Acute Gastroenteritis | Infectious disease | Oct 2026 |
| NCT05831111 | mRNA-1189 | Phase 1 | Epstein-Barr Virus Infection | Infectious disease | Oct 2026 |
| NCT05831111 | mRNA-1195.1 | Phase 1 | Epstein-Barr Virus Infection | Infectious disease | Oct 2026 |
| NCT05095727 | mRNA-3745 | Phase 1 | Glycogen Storage Disease | Metabolic and endocrine | Nov 2026 |
| NCT07863635 | mRNA-1283 | Phase 4 | SARS-CoV-2 | Infectious disease | Dec 2026 |
| NCT07863635 | Tozinameran (mRNA-1273) | Phase 4 | SARS-CoV-2 | Infectious disease | Dec 2026 |
| NCT06655870 | mRNA-0184 | Phase 1 | Healthy Participants | Other | Dec 2026 |
| NCT06585241 | mRNA-1273 Variant-containing Formulation | Phase 4 | SARS-CoV-2 | Infectious disease | Dec 2026 |
| NCT07496450 | mRNA-1018-H5 | Phase 3 | Influenza | Infectious disease | Jan 2027 |
| NCT06592794 | mRNA-1403 | Phase 3 | Acute Gastroenteritis | Infectious disease | Feb 2027 |
| NCT05683457 | mRNA-1647 | Phase 2 | Cytomegalovirus Infection | Infectious disease | Mar 2027 |
| NCT07478952 | mRNA-1189 | Phase 1 | Epstein-Barr Virus | Infectious disease | May 2027 |
| NCT07266558 | mRNA-1283 | Phase 4 | SARS-CoV-2 | Infectious disease | Jun 2027 |
| NCT07266558 | Tozinameran (mRNA-1273) | Phase 4 | SARS-CoV-2 | Infectious disease | Jun 2027 |
| NCT07764237 | mRNA-1365 (Profile 2) | Phase 1 | Respiratory Syncytial Virus (RSV) | Infectious disease | Jul 2027 |
| NCT06880549 | mRNA-4106 | Phase 1 | Advanced Solid Tumors | Oncology | Aug 2027 |
| NCT06880549 | mRNA-4200 | Phase 1 | Advanced Solid Tumors | Oncology | Aug 2027 |
| NCT05164094 | mRNA-1189 | Phase 1 | Epstein-Barr Virus Infection | Infectious disease | Aug 2027 |
| NCT04159103 | mRNA-3927 | Phase 1 | Propionic Acidemia | Metabolic and endocrine | Aug 2027 |
| NCT07737717 | mRNA-1469 | Phase 1 | Ebola-Bundibugyo Virus Disease (Ebola-BDBV) | Infectious disease | Sep 2027 |
| NCT03313778 | mRNA-4157 | Phase 1 | Solid Tumors | Oncology | Nov 2027 |
| NCT07870330 | mRNA-1010 | Phase 1 | Seasonal Influenza | Infectious disease | Dec 2027 |
| NCT07561294 | mRNA-1982 | Phase 2 | Lyme Disease | Infectious disease | Nov 2028 |
| NCT06735248 | mRNA-1195.1 | Phase 2 | Multiple Sclerosis | Neurology | Jan 2029 |
| NCT07808697 | mRNA-1283 | Phase 2 | SARS-CoV-2 | Infectious disease | Aug 2029 |
| NCT05743881 | mRNA-1365 (Profile 2) | Phase 1 | Respiratory Syncytial Virus | Infectious disease | Aug 2029 |
| NCT05743881 | mRNA-1345 | Phase 1 | Respiratory Syncytial Virus | Infectious disease | Aug 2029 |
| NCT05130437 | mRNA-3927 | Phase 1 | Propionic Acidemia | Metabolic and endocrine | Dec 2029 |
| NCT07116616 | mRNA-2808 | Phase 1 | Relapsed or Refractory Multiple Myeloma | Oncology | Jun 2030 |
| NCT05533697 | mRNA-4359 | Phase 1 | Advanced Solid Tumors | Oncology | Feb 2032 |
| NCT03897881 | mRNA-4157 | Phase 2 | Melanoma | Oncology | Nov 2032 |
| NCT05295433 | mRNA-3705 | Phase 1 | Methylmalonic Acidemia | Metabolic and endocrine | Apr 2034 |
Cash and short-term investments of $5.2bn on 2026-09-30; operating cash outflow about $3.6bn a year; runway about 17 months at that burn, to Feb 2028; 3 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Sanofi AstraZeneca MAXVAX Biotechnology Limited Liability Company Enanta Pharmaceuticals Shenzhen Shenxin Biotechnology GSK
CanSino Biologics Anhui Zhifei Longcom Biologic Pharmacy Precigen InventVacc Biologicals MAXVAX Biotechnology Limited Liability Company
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.